1、Annual Completed Clinical Trials ReportFinding Stable Ground in an Ever-evolving Industry LandscapeMay 2025White PaperDrew Muscara,Trialtrove Analyst,Citeline2May 2025 Copyright 2025 Pharma Intelligence UK Limited,a Citeline company(Unauthorized photocopying prohibited)Annual Completed Clinical Tria

2、ls ReportTrialtrove recorded 4,903 industry-sponsored clinical studies from Phase I through Phase III/IV that either completed or attained primary endpoints during 2024.This is a 14.2%increase from the previous year that reported 4,295 completed trials evaluated from 2023,representing the greatest i

3、ncrease in the last eight years(20172023).An additional 1,153 trials were noted as terminated in 2024,marking an 11.9%rise from those recorded in 2023(1,030).Following the prior years increase in completed trials,there is a consecutive rise in the number of studies that reached completed status.As t

4、he volume of studies continually compounds,a deviation from the pattern of alternating trial count increases,in 2021 and 2023,and decreases,in 2020 and 2022,is evident.1For the second year in a row,all therapeutic areas(TAs)exhibited greater trial completions than the year before.Although higher com

5、pleted trial levels were found,vaccines(infectious disease)studies had insubstantial growth compared with other TAs such as oncology and central nervous system(CNS)which saw the most prominent surge in completed trials,respectively.In the post-pandemic landscape,the minimal number of completed vacci

6、ne studies marks a stabilization in COVID-19 related programs.The high performance of the top 20 pharma companies continues to show through the topline trial evaluations.However,with a significant number of completed studies recorded,all other pharma(AOP)have also responded and bolstered their trial